Analytical Data
-
基因名
CLEC-2
-
简介
CLEC1B/CLEC-2 protein is a C-type lectin-like receptor that acts as a platelet receptor and snake venom protein receptor for PDPN in microbial infections. Upon activation, it initiates a signaling cascade involving SRC and SYK kinases, leading to PLCG2 activation. CLEC1B/CLEC-2 Protein, Human (HEK293, N-His) is the recombinant human-derived CLEC1B/CLEC-2, expressed by HEK293, with N-10*His labeled tag. The total length of CLEC1B/CLEC-2 Protein, Human (HEK293, N-His) is 172 a.a..
- Application
-
别名
C-type lectin domain family 1 member B; CLEC1B; CLEC2
-
种属
Human
-
表达系统
HEK293
-
标签
N-10*His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q9P126-1
-
表达区间
Q58-P229
-
蛋白长度
Extracellular Domain
-
分子量
30-38 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC-2 (C-type lectin-like receptor 2) is a pivotal receptor primarily expressed on dendritic cells and platelets, playing a crucial role in the immune system and hemostasis. It is known for its ability to recognize specific glycans found on pathogens and activated platelets, thereby mediating immune responses and thrombosis. The significance of CLEC-2 in various physiological and pathological processes has garnered considerable attention, particularly in tumor immunity and infectious diseases. Research indicates that CLEC-2 is involved in dendritic cell maturation and T-cell activation, influencing how the immune system responds to foreign antigens. Additionally, its role in platelet activation suggests that CLEC-2 could be a potential therapeutic target for anticoagulant strategies. Given the increasing incidence of thromboembolic diseases globally, understanding CLEC-2's structure and function is critical for developing novel treatments. Consequently, recombinant CLEC-2 protein research has become a focal point, aiming to elucidate its molecular mechanisms, interactions, and potential applications in immunotherapy and thrombosis management. Moreover, producing recombinant CLEC-2 enables the exploration of its structural biology and can facilitate the design of specific inhibitors or agonists to modulate its activity in clinical settings. The investigation of CLEC-2 continues to be a promising area of research in immunology and hematology, with implications for enhancing therapeutic strategies against various diseases.
